scholarly journals The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study

2021 ◽  
Author(s):  
Johannes Nossent ◽  
Charles Inderjeeth ◽  
Helen Keen ◽  
David Preen ◽  
Ian Li ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Hospital Admission ◽  
Population Based ◽  
Inhibitor Therapy ◽  
Tnf Inhibitor ◽  
Population Based Study ◽  
Admission Rates

scholarly journals Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population‐based study

2018 ◽  
Vol 20 (6) ◽  
pp. 1066-1068 ◽  
Author(s):  
François Alla ◽  
Nelly Agrinier ◽  
Marc Lavielle ◽  
Patrick Rossignol ◽  
Damien Gonthier ◽  
...  
Keyword(s):  
Heart Failure ◽  
Disease Management ◽  
Hospital Admission ◽  
Disease Management Programme ◽  
Population Based ◽  
Management Programme ◽  
Population Based Study ◽  
Admission Rates ◽  
Regional Disease

AB0741 Non Response to TNF-Inhibitor Therapy in Ankylosing Spondylitis is Associated with Restricted Spinal Mobility

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1146.2-1146
Author(s):  
I. Sari ◽  
R.D. Inman ◽  
J. Chan ◽  
A. Omar ◽  
R. Ayearst ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Inhibitor Therapy ◽  
Spinal Mobility ◽  
Tnf Inhibitor

scholarly journals Trends in disease incidence and survival and their effect on mortality in Scotland: nationwide cohort study of linked hospital admission and death records 2001–2016

BMJ Open ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. e034299
Author(s):  
Paul R H J Timmers ◽  
Joannes J Kerssens ◽  
Jon Minton ◽  
Ian Grant ◽  
James F Wilson ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Heart Disease ◽  
Hospital Admission ◽  
Disease Incidence ◽  
Malignant Neoplasm ◽  
Population Based ◽  
Life Extension ◽  
Socioeconomic Groups ◽  
Admission Rates ◽  
Mortality Improvements

ObjectivesIdentify causes and future trends underpinning Scottish mortality improvements and quantify the relative contributions of disease incidence and survival.DesignPopulation-based study.SettingLinked secondary care and mortality records across Scotland.Participants1 967 130 individuals born between 1905 and 1965 and resident in Scotland from 2001 to 2016.Main outcome measuresHospital admission rates and survival within 5 years postadmission for 28 diseases, stratified by sex and socioeconomic status.Results‘Influenza and pneumonia’, ‘Symptoms and signs involving circulatory and respiratory systems’ and ‘Malignant neoplasm of respiratory and intrathoracic organs’ were the hospital diagnosis groupings associated with most excess deaths, being both common and linked to high postadmission mortality. Using disease trends, we modelled a mean mortality HR of 0.737 (95% CI 0.730 to 0.745) from one decade of birth to the next, equivalent to a life extension of ~3 years per decade. This improvement was 61% (30%–93%) accounted for by improved disease survival after hospitalisation (principally cancer) with the remainder accounted for by lowered hospitalisation incidence (principally heart disease and cancer). In contrast, deteriorations in infectious disease incidence and survival increased mortality by 9% (~3.3 months per decade). Disease-driven mortality improvements were slightly greater for men than women (due to greater falls in disease incidence), and generally similar across socioeconomic deciles. We project mortality improvements will continue over the next decade but slow by 21% because much progress in disease survival has already been achieved.ConclusionMorbidity improvements broadly explain observed mortality improvements, with progress on prevention and treatment of heart disease and cancer contributing the most. The male–female health gaps are closing, but those between socioeconomic groups are not. Slowing improvements in morbidity may explain recent stalling in improvements of UK period life expectancies. However, these could be offset if we accelerate improvements in the diseases accounting for most deaths and counteract recent deteriorations in infectious disease.

scholarly journals Should clinicians pay more attention to the potential underdiagnosis of osteoporosis in patients with ankylosing spondylitis? A national population-based study in Taiwan

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211835 ◽  
Author(s):  
Li-Yu Hu ◽  
Ti Lu ◽  
Pan-Ming Chen ◽  
Cheng-Che Shen ◽  
Yao-Min Hung ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Population Based ◽  
Population Based Study ◽  
National Population

scholarly journals Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0192524 ◽  
Author(s):  
Jeong Seok Lee ◽  
Baek-Lok Oh ◽  
Hee Young Lee ◽  
Yeong Wook Song ◽  
Eun Young Lee
Keyword(s):  
Ankylosing Spondylitis ◽  
Healthcare Expenditure ◽  
Population Based ◽  
Population Based Study

scholarly journals Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Jiayong Ou ◽  
Min Xiao ◽  
Yefei Huang ◽  
Liudan Tu ◽  
Zena Chen ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Ultra Performance Liquid Chromatography ◽  
Tnf Inhibitors ◽  
Inhibitor Therapy ◽  
Tnf Inhibitor ◽  
Before And After ◽  
Metabolomics Study ◽  
Diagnostic Panel ◽  
Selection Operator ◽  
Serum Metabolomics

Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatment. Additionally, we aimed to define reliable serum biomarkers for the diagnosis. We employed an untargeted technique, ultra-performance liquid chromatography-mass spectroscopy (LC-MS), to analyze the serum metabolome of 32 AS individuals before and after 24-week TNF inhibitors treatment, as well as 40 health controls (HCs). Multivariate and univariate statistical analyses were used to profile the differential metabolites associated with AS and TNF inhibitors. A diagnostic panel was established with the least absolute shrinkage and selection operator (LASSO). The pathway analysis was also conducted. A total of 55 significantly differential metabolites were detected. We generated a diagnostic panel comprising five metabolites (L-glutamate, arachidonic acid, L-phenylalanine, PC (18:1(9Z)/18:1(9Z)), 1-palmitoylglycerol), capable of distinguishing HCs from AS with a high AUC of 0.998, (95%CI: 0.992–1.000). TNF inhibitors treatment could restore the equilibrium of 21 metabolites. The most involved pathways in AS were amino acid biosynthesis, glycolysis, glutaminolysis, fatty acids biosynthesis and choline metabolism. This study characterized the serum metabolomics signatures of AS and TNF inhibitor therapy. We developed a five-metabolites-based panel serving as a diagnostic tool to separate patients from HCs. This serum metabolomics study yielded new knowledge about the AS pathogenesis and the systemic effects of TNF inhibitors.

Sign in / Sign up

Export Citation Format

Share Document